Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 67, 183-193
Abstract
No abstract availableKeywords
Funding Information
- NIH/NCI (R01CA152212, R01CA115483, R01EB012569)
- National Natural Science Foundation of China (81101143)
This publication has 48 references indexed in Scilit:
- Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancersAdvanced Drug Delivery Reviews, 2014
- CIP2A is a target of bortezomib in human triple negative breast cancer cellsBreast Cancer Research, 2012
- Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphomaThe Journal of Antibiotics, 2011
- Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast CancerClinical Breast Cancer, 2010
- Reversibly Stabilized Multifunctional Dextran Nanoparticles Efficiently Deliver Doxorubicin into the Nuclei of Cancer CellsAngewandte Chemie International Edition, 2009
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivoClinical Cancer Research, 2008
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomyBritish Journal of Cancer, 2008
- Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefitsAnnals of Oncology, 2006
- Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathwayOncogene, 1999
- A NEW CONCEPT FOR MACROMOLECULAR THERAPEUTICS IN CANCER-CHEMOTHERAPY - MECHANISM OF TUMORITROPIC ACCUMULATION OF PROTEINS AND THE ANTITUMOR AGENT SMANCS1986